Daratumumab in Treatment of PGNMID and C3 GN

Key facts

Sponsor

Fernando Fervenza

Principal Investigator

Fernando C Fervenza, MD

Mayo Clinic

Intervention

Daratumumab(drug)

Enrollment

12 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2020

Study locations (1)

• Mayo Clinic, Rochester, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for C3 glomerulonephritis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06209736
  Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
  Omeros Corporation
• ACTIVE NOT RECRUITINGPHASE3NCT05809531
  An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
  Apellis Pharmaceuticals, Inc.
• RECRUITINGPHASE2NCT04183101
  Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
  Region Skane
• RECRUITINGPHASE3NCT03955445
  Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
  Novartis Pharmaceuticals

See all trials for C3 glomerulonephritis →